liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
University of Sydney.
University of Sydney.
Linköping University, Department of Medical and Health Sciences, Pharmacology. Linköping University, Faculty of Health Sciences.
University of Sydney.
Show others and affiliations
2011 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 71, no 17, 5871-5880 p.Article in journal (Refereed) Published
Abstract [en]

The metal-chelating compound Dp44mT is a di-2-pyridylketone thiosemicarbazone (DpT) which displays potent and selective antitumor activity. This compound is receiving translational attention, but its mechanism is poorly understood. Here, we report that Dp44mT targets lysosome integrity through copper binding. Studies using the lysosomotropic fluorochrome acridine orange established that the copper-Dp44mT complex (Cu[Dp44mT]) disrupted lysosomes. This targeting was confirmed with pepstatin A-BODIPY FL, which showed redistribution of cathepsin D to the cytosol with ensuing cleavage of the proapoptotic BH3 protein Bid. Redox activity of Cu[Dp44mT] caused cellular depletion of glutathione, and lysosomal damage was prevented by cotreatment with the glutathione precursor N-acetylcysteine. Copper binding was essential for the potent antitumor activity of Dp44mT, as coincubation with nontoxic copper chelators markedly attenuated its cytotoxicity. Taken together, our studies show how the lysosomal apoptotic pathway can be selectively activated in cancer cells by sequestration of redox-active copper. Our findings define a novel generalized strategy to selectively target lysosome function for chemotherapeutic intervention against cancer.

Place, publisher, year, edition, pages
American Association for Cancer Research , 2011. Vol. 71, no 17, 5871-5880 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-70738DOI: 10.1158/0008-5472.CAN-11-1218ISI: 000294454700028OAI: diva2:441423
Funding Agencies|National Health and Medical Research Council||Cancer Institute NSW||Available from: 2011-09-16 Created: 2011-09-16 Last updated: 2011-09-16

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Brunk, Ulf
By organisation
PharmacologyFaculty of Health Sciences
In the same journal
Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 59 hits
ReferencesLink to record
Permanent link

Direct link